• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Zynex Announces Partnership To Conduct Business with Veterans Affairs (VA) Medical Centers, the Largest Healthcare Network in the United States

    12/17/24 9:15:00 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ZYXI alert in real time by email

    VA Spending on Hospital and Medical Care Exceeds $112 Billion Annually

    ENGLEWOOD, Colo., Dec. 17, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced a new partnership to conduct business with Veterans Affairs Medical Centers (VAMCs) across the United States. This collaboration reflects Zynex's commitment to improving access to high-quality care for our nation's veterans.

    Zynex

    It is estimated that the VA spends over $112 billion annually on healthcare. This partnership enables Zynex to bring its advanced pain management solutions to a critical and growing market, with the VA's system alone servicing over 9 million enrolled veterans. Currently, less than 1% of Zynex's sales are from VAMCs and the partnership provides an opportunity to significantly expand sales into the largest healthcare network in the U.S.

    With 171 VAMCs and over 1,100 outpatient facilities nationwide, the Department of Veterans Affairs serves millions of veterans annually. Additionally, there are approximately 700 Military Treatment Facilities (MTFs) operated by the Department of Defense, forming an extensive network for addressing the healthcare needs of service members and their families.

    "Our partnership to do business with the VA represents a significant milestone in expanding access to non-opioid pain management solutions for those who have served our country," said Thomas Sandgaard, CEO, Founder, and Chairman. "Working with the VA provides us with access to the largest healthcare network in the United States and we are honored to help enhance the quality of care for veterans nationwide."

    As part of this collaboration, Zynex's sales team will work closely with healthcare providers within the VA and MTF networks to deliver its full product suite of innovative, pain management treatments designed to improve patient outcomes while addressing the unique pain management needs of these populations.

    About Zynex, Inc.

    Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.

    Safe Harbor Statement

    This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.

    Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward-looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our products on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy and other risks described in our filings with the Securities and Exchange Commission including but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2023 as well as our quarterly reports on Form 10-Q and current reports on Form 8-K.

    Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

    Investor Relations Contact:

    Brian Prenoveau, CFA

    MZ Group – MZ North America

    [email protected]

    +561 489 5315

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/zynex-announces-partnership-to-conduct-business-with-veterans-affairs-va-medical-centers-the-largest-healthcare-network-in-the-united-states-302333802.html

    SOURCE Zynex, Inc.

    Get the next $ZYXI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZYXI

    DatePrice TargetRatingAnalyst
    8/1/2025$3.70Neutral → Buy
    Ladenburg Thalmann
    8/1/2025Buy → Neutral
    H.C. Wainwright
    3/12/2025$11.00 → $5.50Outperform → Sector Perform
    RBC Capital Mkts
    3/12/2025Buy → Neutral
    Ladenburg Thalmann
    10/16/2023$13.00Outperform
    RBC Capital Mkts
    1/6/2023$10.00 → $18.00Neutral → Overweight
    Piper Sandler
    2/28/2022$15.50 → $10.00Buy
    B. Riley Securities
    2/25/2022$22.00 → $20.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ZYXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zynex upgraded by Ladenburg Thalmann with a new price target

    Ladenburg Thalmann upgraded Zynex from Neutral to Buy and set a new price target of $3.70

    8/1/25 8:25:35 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Zynex from Buy to Neutral

    8/1/25 8:12:40 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Zynex from Outperform to Sector Perform and set a new price target of $5.50 from $11.00 previously

    3/12/25 7:36:55 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ZYXI
    SEC Filings

    View All

    $ZYXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ZYXI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zynex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - ZYNEX INC (0000846475) (Filer)

    12/18/25 4:30:11 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ZYNEX INC (0000846475) (Filer)

    12/16/25 8:09:16 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Zynex Inc.

    10-Q - ZYNEX INC (0000846475) (Filer)

    11/17/25 5:21:57 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Aronzon Paul

    3 - ZYNEX INC (0000846475) (Issuer)

    11/20/25 8:58:24 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Wise Bret W

    3 - ZYNEX INC (0000846475) (Issuer)

    10/17/25 9:46:04 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Bajaj Vikram Singh

    3 - ZYNEX INC (0000846475) (Issuer)

    9/3/25 6:19:15 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex Financial Restructuring Puts Company on Path to Long-Term Success

    ENGLEWOOD, Colo., Dec. 16, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation today announced it has voluntarily entered into a Chapter 11 court-supervised financial restructuring with the support of new financing from the Company's lenders. "Today we take the next step in creating a new future for Zynex," said Steven Dyson, Chief Executive Officer. "This financing demonstrates the confidence our lenders have in our business and

    12/16/25 8:00:00 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex Reports Third Quarter 2025 Financial Results

    ENGLEWOOD, Colo., Nov. 17, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, and rehabilitation, today reported its financial and operational results for the third quarter ended September 30, 2025. Management Commentary and Recent Events "Since joining the Company in August, the new management team has worked tirelessly to address the business and compliance challenges at Zynex while creating a new future for all our company," said Steven Dyson,

    11/17/25 5:15:00 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex Announces Strategic Initiatives: Engagement of Province, Appointment of Paul Aronzon to Board of Directors, and Formation of Special Committee

    ENGLEWOOD, Colo., Nov. 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation, today announced a series of strategic initiatives aimed at positioning Zynex for long-term success. Zynex has engaged Province, LLC, an internationally recognized financial advisory firm, to assist on evaluating a range of strategic alternatives, including potential capital raising opportunities and recapitalization and restructuring strategies. In add

    11/14/25 8:15:00 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ZYXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Disbrow Joshua R. bought $58,233 worth of shares (7,000 units at $8.32), increasing direct ownership by 11% to 72,000 units (SEC Form 4)

    4 - ZYNEX INC (0000846475) (Issuer)

    7/30/24 6:25:26 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ZYXI
    Leadership Updates

    Live Leadership Updates

    View All

    Zynex Announces Strategic Initiatives: Engagement of Province, Appointment of Paul Aronzon to Board of Directors, and Formation of Special Committee

    ENGLEWOOD, Colo., Nov. 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation, today announced a series of strategic initiatives aimed at positioning Zynex for long-term success. Zynex has engaged Province, LLC, an internationally recognized financial advisory firm, to assist on evaluating a range of strategic alternatives, including potential capital raising opportunities and recapitalization and restructuring strategies. In add

    11/14/25 8:15:00 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex Announces Appointment of Bret Wise to Board of Directors as Audit Committee Chair

    ENGLEWOOD, Colo., Oct. 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the appointment of Bret Wise to its Board of Directors. Mr. Wise will also serve as Chair of the Audit Committee. "Bret Wise is a great addition to our Board of Directors as the Chair of our Audit Committee as we continue to refocus the Zynex mission and vision around patient and customer success with a renewed comm

    10/14/25 6:07:00 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex Announces Arrival of Steven Dyson as CEO and Appointment of New Leadership in Key Roles

    ENGLEWOOD, Colo., Aug. 18, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the arrival of newly appointed CEO, Steven Dyson, and the appointment of several new leaders at the Company.  On June 30, 2025, the Company announced the Board's appointment of Steven Dyson as the incoming CEO.  Since that time, Mr. Dyson and Thomas Sandgaard, the Chairman of the Board, have been actively working wi

    8/18/25 8:15:00 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ZYXI
    Financials

    Live finance-specific insights

    View All

    Zynex Reports Third Quarter 2025 Financial Results

    ENGLEWOOD, Colo., Nov. 17, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, and rehabilitation, today reported its financial and operational results for the third quarter ended September 30, 2025. Management Commentary and Recent Events "Since joining the Company in August, the new management team has worked tirelessly to address the business and compliance challenges at Zynex while creating a new future for all our company," said Steven Dyson,

    11/17/25 5:15:00 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex Sets Third Quarter 2025 Earnings Call

    ENGLEWOOD, Colo., Nov. 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation, will hold a conference call on Tuesday, November 18, 2025 at 9:00 AM Eastern Time to discuss its financial results for the third quarter ended September 30, 2025. Financial results will be issued in a press release prior to the call. Zynex management will host the conference call. Date: Tuesday, November 18, 2025Time: 9:00 AM Eastern Time (7:00 PM Moun

    11/14/25 8:00:00 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex Reports Second Quarter 2025 Financial Results

    ENGLEWOOD, Colo., July 31, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the second quarter ended June 30, 2025. Management Commentary  "In the second quarter of 2025, we completed two transformational events. First, we appointed Steven Dyson as our new CEO. Steven brings over 25 years of experience in the medical technology sector, primarily thro

    7/31/25 4:01:00 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ZYXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Zynex Inc. (Amendment)

    SC 13D/A - ZYNEX INC (0000846475) (Subject)

    5/24/23 6:26:30 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care